Revolution Medicines (RVMDW) Cash from Financing Activities (2019 - 2026)

Revolution Medicines' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $238.7 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 27216.25% year-over-year to $238.7 million; the TTM figure through Mar 2026 stood at $859.4 million (down 10.43% YoY), while the FY2025 annual figure was $621.5 million, down 35.22% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $238.7 million, down from $365.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $873.8 million in Q4 2024, with the low at -$1.6 million in Q3 2025.
• The 5-year median for Cash from Financing Activities is $64.6 million (2023), against an average of $197.1 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities jumped 106196.72% in 2023, then slumped 102.06% in 2025.
• Revolution Medicines' Cash from Financing Activities stood at $51.4 million in 2022, then soared by 1534.16% to $839.4 million in 2023, then gained by 4.1% to $873.8 million in 2024, then sank by 58.15% to $365.7 million in 2025, then slumped by 34.71% to $238.7 million in 2026.
• Business Quant data shows RVMDW's Cash from Financing Activities at $238.7 million in Q1 2026, $365.7 million in Q4 2025, and -$1.6 million in Q3 2025.